Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Four-Gene Blood Test Rules Out Bacterial Lung Infection

By LabMedica International staff writers
Posted on 10 Dec 2025

Lower respiratory tract infections (LRTIs) are among the most common reasons for antibiotic prescriptions, yet distinguishing bacterial infections from viral ones remains notoriously difficult. More...

Misclassification frequently leads to unnecessary antibiotic use, higher healthcare costs, and increased antimicrobial resistance. Now, a new four-gene blood test offers a precise and rapid way to rule out bacterial LRTIs, enabling clinicians to make more accurate treatment decisions.

Researchers at the University of Rochester (Rochester, NY, USA) have developed a molecular diagnostic tool that evaluates the host immune response rather than searching directly for pathogens. Their transcriptomic approach identifies a unique pattern of gene expression that reliably differentiates bacterial from viral infections, providing a powerful complement to traditional diagnostic methods.

Using high-throughput RNA sequencing, the team examined hundreds of adults presenting with LRTI-like symptoms. Thousands of transcripts varied between bacterial and viral infections, but researchers eventually distilled these into a highly accurate four-gene signature optimized for clinical use. One gene strongly reflects bacterial recognition pathways, while the remaining three sharpen the test’s overall discriminatory power. This minimal panel enables rapid and cost-effective testing suitable for routine workflows.

The diagnostic accuracy has major clinical implications. By confidently ruling out bacterial infection, clinicians can withhold antibiotics when they are not needed, preventing unnecessary exposure and slowing the rise of antibiotic resistance. At the same time, patients who do have bacterial disease can be identified more appropriately, improving treatment prioritization and resource allocation.

The test requires only a blood sample, making it easy to deploy in emergency departments, outpatient clinics, and settings with limited laboratory infrastructure. With further development, the method could be adapted for point-of-care testing to support timely decision-making even in remote or resource-restricted environments.

In addition to its clinical utility, the study, published in Nature Communications, also highlights key differences in host immune pathways activated by bacterial versus viral infections, offering deeper insight into the biology of infectious disease. Researchers emphasize that while the four-gene signature enhances diagnostic precision, it must be interpreted alongside clinical context to guide care appropriately.

Future work will involve validating the assay across diverse populations and healthcare systems and moving toward regulatory approval and commercial development. If widely adopted, this diagnostic could transform respiratory infection management by aligning treatment with true underlying pathology and helping preserve antibiotic effectiveness worldwide.

Related Links:
University of Rochester


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.